Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) EBITDA Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBITDA Margin for 5 consecutive years, with 17372.06% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 17372.06% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5849.16% through Dec 2025, changed N/A year-over-year, with the annual reading at 10065.38% for FY2023, 877392.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 17372.06% at Pliant Therapeutics, up from 3222.82% in the prior quarter.
  • The five-year high for EBITDA Margin was 17372.06% in Q4 2025, with the low at 16976.61% in Q2 2023.
  • Average EBITDA Margin over 4 years is 86.54%, with a median of 1256.04% recorded in 2021.
  • The sharpest move saw EBITDA Margin skyrocketed 67844bps in 2022, then crashed -1637820bps in 2023.
  • Over 4 years, EBITDA Margin stood at 1235.22% in 2021, then tumbled by -42bps to 1758.98% in 2022, then tumbled by -865bps to 16976.61% in 2023, then surged by 202bps to 17372.06% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 17372.06%, 3222.82%, and 5372.06% for Q4 2025, Q3 2025, and Q2 2025 respectively.